Apligraf Improves Reimbursement for Patients
- Wed, 4/18/12 - 9:24am
- 0 Comments
- 440 reads
Apligraf® (Organogenesis Inc, Canton, MA) has established improved coverage from multiple payors, improving access to care for millions of patients suffering from chronic, non-healing wounds. This is the only cell-based product with the Food and Drug Administration (FDA) approval for the treatment of both diabetic foot ulcers and venous leg ulcers.
Apligraf is the first bio-engineered living cell-based product to have received FDA approval for treatment of diabetic foot ulcers and venous leg ulcers. Clinical studies of the application were based on up to five treatments, comprising weekly assessments and/or applications, over a 12-week period.
This week, Apligraf will be showcased at the 25th Annual Symposium on Advanced Wound Care and Wound Healing Society (SAWC/WHS 2012), held April 19-22 in Atlanta, GA. Organogenesis will be featuring Apligraf at Booth #623 and its Medical Affairs team at Booth #540, as well as hosting events during the annual conference and answering questions about increased reimbursement.
Visit http://www.organogenesis.com for more information.